



**Response to the Appraisal Consultation Document:
Tenofovir disoproxil fumarate for the treatment of hepatitis B**

March 2009

**This response is submitted on behalf of
Hepatitis B Foundation UK**

We are delighted with the Appraisal Committee's preliminary recommendations. Hopefully the end result will be a positive Final Appraisal Determination and the publishing of final guidance. This technology is a very important new treatment option for chronic hepatitis B and the sooner it is freely available on the NHS the better it will be for patients.

1. Do you consider that all of the relevant evidence has been taken into account?

Yes, the Appraisal Committee has taken into account the evidence from clinicians and patient experts, as well as data available on the clinical and cost effectiveness of the technology.

2. Do you consider that the summaries of clinical and cost effectiveness are reasonable interpretations of the evidence, and that the preliminary views on the resource impact and implications for the NHS are appropriate?

Yes, summaries are reasonable interpretations and preliminary views are appropriate.

3. Do you consider that the provisional recommendations of the Appraisal Committee are sound and constitute a suitable basis for the preparation of guidance to the NHS?

Most definitely, yes.

4. Are there any equality related issues that need special consideration that are not covered in the ACD?

No.